Related Experiment Video
Updated: Apr 14, 2026

An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions
Published on: March 14, 2016
Antagonist Binding Actively Disrupts Interleukin-1 Receptor Dynamics to Block Co-receptor Recruitment
Chandran Nithin1, Ayomide Fasemire1, Sebastian Kmiecik1
1Biological and Chemical Research Centre, Faculty of Chemistry, University of Warsaw, 02-089 Warsaw, Poland.
Interleukin-1 receptor type 1 (IL1R1) signaling is controlled by dynamic receptor changes. Antagonists actively prevent co-receptor binding by altering receptor flexibility, not just by failing to activate it.
Area of Science:
- Biochemistry
- Molecular Biology
- Structural Biology
Background:
- Interleukin-1 receptor type 1 (IL1R1) regulates inflammatory signaling.
- Understanding how agonists and antagonists yield opposite outcomes at the same binding site is unclear.
- Existing structural data lack dynamic insights into antagonist inhibition.
Purpose of the Study:
- To investigate the dynamic mechanisms underlying IL1R1 activation and antagonism.
- To compare the intrinsic dynamics of IL1R1 in unbound, agonist-bound, antagonist-bound, and co-receptor-bound states.
- To elucidate how antagonists prevent co-receptor recruitment.
Main Methods:
- All-atom molecular dynamics simulations.
- Multiscale flexibility modeling using CABS-flex.
- Systematic comparison of IL1R1 dynamics across different binding states.
Main Results:
- Both agonists and antagonists bind the same IL1R1 interface but induce distinct dynamic responses.
- Agonist binding stabilizes interdomain coupling, promoting a signaling-competent state.
- Antagonist binding increases D3 domain flexibility at the co-receptor interface, blocking activation.
Conclusions:
- IL1R1 antagonism is an active, allosteric, dynamics-driven process.
- Receptor dynamics are crucial for controlling IL1R1 signaling outcomes.
- This study provides a mechanistic framework reconciling structural and functional data.
More Related Videos
06:56A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4
Published on: March 10, 2018
09:40Co-immunoprecipitation Assay for Studying Functional Interactions Between Receptors and Enzymes
Published on: September 28, 2018
Related Concept Videos
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Drug-Receptor Interactions
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
The Two-State Receptor Model
The binding affinity of a drug determines its interaction with...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...